TSRI announces new agreement with Janssen to focus on flu virus project
Under the terms of the agreement with the Johnson & Johnson subsidiary, TSRI will conduct infectious disease research and Janssen will receive certain license rights to the results of the research. Janssen will collaborate in the influenza research through its Crucell Vaccine Institute.
"We're delighted to partner with Janssen in this work that could have a significant impact on human health," Michael Marletta, the president and CEO of TSRI, said. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."
The agreement will build on research previous collaborative by TSRI and CVI which resulted in several high-impact publications.
"This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs," Scott Forrest, TSRI's vice president for business development, said.
According to the U.S. Centers for Disease Control and Prevention, seasonal influenza typically causes more than 200,000 hospitalizations and 36,000 deaths annually in the U.S.